Physician’s Briefing Weekly Coronavirus Roundup
Three FDA Advisers Quit Over Agency Approval of Aduhelm
Several experts have said the available evidence about Aduhelm raises significant doubts about its effectiveness
Weight Control Product Use in Adolescence Ups Risk for Later Eating Disorder
Findings seen among teens followed for 10 years into early adulthood
Inhaled Nitrous Oxide Explored for Treatment-Resistant Depression
In phase 2 trial, 25 percent nitrous oxide comparable to 50 percent nitrous oxide for reducing symptoms, but with fewer adverse effects
Review IDs Reasons for Disparities in Headache Treatment
Factors that contribute to disparities include racism, socioeconomic status and insurance status, geographic disparities
Neurological, Neuropsychiatric Symptoms Common in COVID-19
Symptoms with the highest prevalence included anosmia, weakness, fatigue, dysgeusia, myalgia, and depression
Houston Methodist Suspends Nearly 200 Workers Who Refuse COVID-19 Vaccines
Nearly 25,000 workers met Monday's deadline to be fully immunized, but 178 failed to do so and were suspended
Gap Between Mortality in Rural and Urban Areas Has Increased
Difference increased in age-adjusted mortality rates between large metropolitan areas, rural areas from 1999 to 2019
Buprenorphine Rx Activity Varies Widely Among Clinicians
Less than 5 percent of prescribers account for half of all buprenorphine treatment in the country
FDA Approves Aduhelm for Alzheimer Disease
Agency says it has granted approval on the condition that drug maker Biogen conduct a new clinical trial
